Advocacy intelligence hub — real-time data for patient organizations
Assistance Publique - Hôpitaux de Paris
Pharming Technologies B.V. — PHASE3
Joenja: FDA approved
treatment of activated phosphoinositide 3-kinase delta (PI3K delta) syndrome (APDS) in adult and pediatric patients 12 years of age and older
Pharming Technologies B.V. — PHASE3
Magentiq Eye LTD
General and Teaching Hospital Celje — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Joenja
Pharming Technologies B.V.
Joenja
(leniolisib)Orphan drugPharming Technologies B.V.
12.1 Mechanism of Action Leniolisib inhibits PI3K-delta by blocking the active binding site of PI3K-delta. In cell-free isolated enzyme assays, leniol...
Sven Kracker, PHD
Institut National de la Santé Et de la Recherche Médicale, France
Joan C Marini, M.D., M.D., Ph.D
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
📍 BETHESDA, MD
Anna Šedivá, MD
Motol University
Virgil Dalm, MD
Erasmus Medical Center
Marco Pappagallo, MD, MD
Icahn School of Medcine at Mount Sinai
📍 NEW YORK, NY
Angela Dispenzieri, M.D., M.D
Mayo Clinic
📍 ROCHESTER, MN